Biomedical subjects

A I Schweid

Publications and source records attributed to A I Schweid.

13 recordsLinked to original sources

PubMed1986

An inflammatory axonopathy of the myenteric plexus producing a rapidly progressive intestinal pseudoobstruction.

A previously well 39-yr-old man presented with a 4-wk history of abdominal pain, nausea, vomiting, and weight loss. An upper gastrointestinal examination showed retained food in the stomach and duodenal dilatation. A radioisotope meal showed little gastric emptying; esophageal manometry was normal. Because of persistent symptoms, a duodenojejunostomy was done. However, the patient remained symptomatic and after an episode of profuse vomiting, aspirated and died 10 wk after initial presentation. At autopsy, no tumor was found. Hematoxylin and eosin stains throughout the gastrointestinal tract showed many lymphocytes and plasma cells within the myenteric plexus. Silver stains showed the argyrophilic and argyrophobic neurons to be normal, but axons showed beading, fragmentation, and dropout in all areas. We therefore concluded the following: intestinal pseudoobstruction can be caused by an inflammatory neuropathy of the myenteric plexus, not associated with a distant carcinoma, and this process produced an axonopathy while sparing neuron bodies.

Adult↗

PubMed1982

Survival among women with endometrial cancer: a comparison of estrogen users and nonusers.

In order to determine the role of postmenopausal estrogen use in survival of patients with endometrial cancer, we identified, through a population-based tumor registry serving the area, all white women in King County, Washington, aged 50 to 74, who developed endometrial cancer between January, 1975, and April, 1976 (N = 363). Estrogen use prior to diagnosis and survival status were ascertained through personal interview, medical records of private physicians, and registry follow-up data. The 4-year relative survival ratio in estrogen users was 1.05 compared to 0.898 in nonusers. Overall, after adjustment for age, the survival in estrogen users was significantly better than in nonusers (chi 2 = 30.5; p much less than 0.0001). While estrogen use may predispose to an increased incidence of endometrial cancer, it appears that such use does not lead to increased mortality from this condition.

Aged↗

PubMed1979

Endometrial cancer in relation to patterns of menopausal estrogen use.

Female residents of King County, Washington, in whom endometrial cancer developed between January 1975 and April 1976 were interviewed concerning prior use of menopausal estrogens. Their responses were compared with those of a random sample of women from the same population. Among current estrogen users, endometrial cancer risk was strongly related to duration of use; although only a minimal elevation of risk was present during the first two years, there was a rapid rise to a 20-fold excess after about ten to 15 years. Cessation of estrogen use led to a decline in incidence of endometrial cancer within several years, but the risk remained higher than in nonusers through the first decade after administration of the drug was stopped. Risk was elevated whether or not the regimen was cyclic and whether conjugated or other types of estrogens had been used. Dosages of less than 0.625 mg/day of conjugated estrogens produced a smaller increase in risk than did other dosages.

Aged↗

PubMed1978

Incidence of endometrial carcinoma in King County, Washington: a standardized histologic review.

Previously diagnosed tumor specimens from 35- to 74-year-old female patients with endometrial cancer who were residents of King County, Washington, during the first 6 months of 1975 were reviewed by a single pathologist using uniform criteria for the assessment of cancer. Routinely reported incidence of this tumor in this population was judged to be inflated, the annual incidence rate (excluding carcinoma in situ) falling from 108.2 to 88.5 per 100,000 women after the exclusion of cases found not to be unequivocally malignant. This rate nonetheless represented a large increase over the rate of 47.3 per 100,000 observed in the U.S. Third National Cancer Survey just 5 years earlier. We concluded that U.S. pathologists in the 1970's may have been using more liberal criteria by which to diagnose endometrial cancer, but that such a change could only account for a small part of the rising incidence of the disease.

Adenocarcinoma↗

PubMed1976